Cytovale Inc. will expand its partnership with the Biomedical Advanced Research and Development Authority, or BARDA, to examine the use of Cytovale’s Rapid Sepsis Diagnostic System for diagnosing seps...

Hollis O’Neal, MD, pulmonary-critical care expert, Our Lady of the Lake, and the national primary investigator for the Cytovale early sepsis detection system, discusses sepsis and COVID-19 and provide...

The Biomedical Advanced Research and Development Authority (BARDA) has hit an organization with Cytovale to build up a quick demonstrative framework for sepsis as a major aspect of the COVID-19 pandem...

Cytovale has received $3.8 million from HHS’ Biomedical Advanced Research and Development Authority (BARDA) for a study of its rapid-sepsis test for COVID-19 patients....

The Biomedical Advanced Research and Development Authority (BARDA) has struck a partnership with Cytovale to develop a rapid diagnostic system for sepsis as part of the COVID-19 pandemic response....

Expansion of BARDA funding will help fund Cytovale pilot study for innovative rapid sepsis diagnostic system that delivers results in under 10 minutes...

Medical cell technology company Cytovale is set to conduct a pilot study of its rapid diagnostic test for sepsis in patients with suspected SARS-CoV-2 and other respiratory infections. The study is be...

Medical technology company Cytovale announced Thursday it has received an additional $3.8 million to fund a pilot study for its rapid sepsis diagnostic system for patients with respiratory infections....

US-based medical technology company Cytovale, Inc has expanded a partnership with the Biomedical Advanced Research and Development Authority (BARDA)...

So far, O’Neal and his team have enrolled 280 patients in their pilot study, and most of them are suspected coronavirus patients. Researchers will use technology from a California-based company, Cytov...

Cytovale Inc., a San Francisco-based medical technology company, has snagged an additional $3.83 million in funding from the U.S. Department of Health and Human Services’ Biomedical Advanced Research ...

Cytovale Inc., a San Francisco-based medical technology company, has picked up $15 million in financing to advance its technology that enables the early detection of sepsis in the emergency department...

The Biomedical Advanced Research and Development Authority (BARDA) announced that it will provide Cytovale of San Francisco an initial $3.4 million, with an option for an additional $4.17 million, to ...

To advance the development of a test that may be able to diagnose sepsis in less than 10 minutes, the U.S. Department of Health and Human Services (HHS) will partner with Cytovale of San Francisco....

The funding is intended to support advancement of its tool for early detection of sepsis in the emergency department....

Cytovale, Inc., a San Francisco, Calif.-based medical technology company dedicated to innovating diagnostics using cell mechanics and machine learning, raised $15m in financing....

Cytovale today announced a $15 million financing for its sepsis-detecting technology for use in the emergency department....

Cytovale announced today it has received a total of $15 million in financing to advance its technology for the early detection of sepsis in the emergency department....